Compare Repligen Corporation Common Stock (RGEN) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Trip.com Group Ltd — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while Trip.com Group Ltd trades at $39.23 (market cap $24.60B). The key difference: Trip.com Group Ltd is far larger — about 2.2× Repligen Corporation Common Stock's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Trip.com Group Ltd for 80 Days on average.
| RGEN | TCOM | |
|---|---|---|
Market Cap | $11.14B | $24.60B |
Volume | 1,259,263 | 1,981,955 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $78.96 |
52-Week Low | $102.87 | $37.96 |
Typical Hold Time | 0 Days | 80 Days |
Enterprise Value | $11.02B | $16.75B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TCOM trades at $38.88, up 0.31% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 7.48, net income margin of 36.9%, and robust revenue growth from $20.0B in 2022 to $62.4B in 2025. Recent Q2 2026 earnings beat expectations at $1.07 per share, though Q1 and Q4 2025 missed. Cash flow remains positive with $7.11B net cash flow in 2024, and the balance sheet is healthy with total assets of $242.58B and debt-to-asset ratio improving to 16.37%.
The outlook is mixed: analyst consensus is bullish with a $56.64 price target and 70.45% buy ratings, but regulatory risks and recent antitrust fines pose challenges. Earnings growth and international expansion are key catalysts, yet competition and market volatility require caution. The stock presents value given low valuations, but investors must weigh regulatory headwinds against fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
